Ustekinumab

• BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch Pending
  2024-514848-88-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial Pending
  2024-514964-24-00 Phase III 1 country University Hospital Of Clermont-Ferrand
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 Phase III/IV 12 countries Bristol-Myers Squibb Services Unlimited Company
• A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting
  2024-515706-77-00 Phase III 8 countries Janssen Cilag International
• MOVE-IT Recruiting
  2024-517123-39-00 Phase IV 1 country Odense University Hospital
• Evaluation of the efficacy and safety of dual biological therapy in patients with refractory Crohn's disease resistant to induction (FLAMING… Recruiting
  2023-506626-37-00 Phase II 1 country Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
• Comparison of ustekinumab, infliximab and COMBinatiOn therapy in moderately-to-severely active Ulcerative Colitis – the head-to-head COMBO-U… Recruiting
  2023-506452-25-00 Phase II 1 country Medical University Of Lodz
• A study to learn how bimekizumab works in children and teenagers with moderate to severe plaque psoriasis Recruiting
  2023-503859-10-00 Phase III 8 countries UCB Biopharma
• A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting
  2023-509096-16-00 Phase IV 8 countries Alimentiv Inc.
• Prevention of postoperative endoscopic disease recurrence in Crohn’s disease: a multicentric study that compares the systematic start of bio… Recruiting
  2022-500311-39-00 Phase IV 2 countries UZ Leuven
• An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting
  2023-508251-39-00 Phase III 2 countries Universitaetsklinikum Erlangen AöR
• A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended
  2023-509239-19-00 Phase III 7 countries Janssen Cilag International
• A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Year… Ended
  2022-501067-40-00 Phase III 7 countries Janssen - Cilag International
• An Open-Label Extension and long-term efficacy and safety monitoring study of patients with Crohn's disease previously included in the loss … Ended
  2024-514326-23-00 Phase III/IV 1 country Belgian IBD Research and Development
• A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended
  2022-501645-70-00 Phase III 14 countries Abbvie Deutschland GmbH & Co. KG
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended
  2023-504736-18-00 Phase II/III 13 countries Janssen - Cilag International
• PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease Ended
  2024-513647-86-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Ped… Ended
  2023-507144-36-00 Phase III 7 countries Janssen - Cilag International
• A study to test whether BI 706321 combined with ustekinumab helps people with Crohn's Disease Ended
  2024-512756-38-00 Phase II 6 countries Boehringer Ingelheim International GmbH
• A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disea… Ended
  2023-504156-10-00 Phase III 3 countries Abbvie Deutschland GmbH & Co. KG
• Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ustek… Ended
  2023-504978-38-00 Phase III 4 countries Janssen - Cilag International
• A Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ust… Ended
  2023-504977-19-00 Phase III 4 countries Janssen - Cilag International
• Evaluating the efficacy and safety of hyperbaric oxygen therapy as an adjuvant treatment compared to biologic therapy alone in moderate to s… Ended
  2023-507450-32-00 Phase III 1 country Medical University Of Gdansk

Showing 1–23 of 23 trials